CD19 and autoimmune disease: Anti-CD20 antibodies historically were used as therapeutic agents for NMOSD10,11; however, B-cell depletion with anti-CD19 monoclonal antibodies offers an attractive treatment approach in autoantibody-driven autoimmune diseases because the pattern of CD19 expression on B cells is broader than that of CD20.12